(Q80381394)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

1 reference

cutaneous B-cell lymphoma

1 reference

Mohsin N

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Budruddin M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Kamble P

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Khalil M

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Pakkyarra A

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jha A

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Mohammed E

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ahmed H

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ahmed J

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Thomas S

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Campistol JM

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Daar A

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

Transplantation Proceedings

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

1267-1271

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Therapeutic targets: MTOR and related pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Post-transplant de novo malignancies in renal transplant recipients: the past and present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

[Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Immunosuppressive drugs and the risk of cancer after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Posttransplantation lymphoproliferative disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Acyclovir inhibition of Epstein-Barr virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

More on virostatic therapy for advanced lymphoproliferation associated with Epstein-Barr virus in an HIV-infected patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Sirolimus-induced remission of posttransplantation lymphoproliferative disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.03.092

10.1016/J.TRANSPROCEED.2007.03.092

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17524950%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference